{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:13:31Z","timestamp":1793909611583,"version":"4.8.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bioorg.2026.109486","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:54:41Z","timestamp":1767945281000},"page":"109486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Discovery of novel pyridazinone derivatives as EGFRWT\/ EGFRT790M kinase inhibitors; design, synthesis, antitumor evaluation, and molecular dynamic simulations"],"prefix":"10.1016","volume":"170","author":[{"given":"Sara Y.","family":"Ewieda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaymaa G.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled M.","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohnad","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa Ali","family":"Eltayb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed T.M.","family":"Nemr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.109486_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109486_bb0010","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107403","article-title":"Discovery of novel Pyrazole-based urea\/Thiourea derivatives as multiple targeting VEGFR-2, EGFRWT, EGFRT790M tyrosine kinases and COX-2 inhibitors, with anti-cancer and anti-inflammatory activities","volume":"147","author":"Fadaly","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108563","article-title":"Design and synthesis of new pyrazole hybrids linked to oxime and nitrate moieties as COX-2, EGFRL858R\/T790M inhibitors and nitric oxide donors with dual anti-inflammatory\/anti-proliferative activities","volume":"161","author":"Fadaly","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0025","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41416-020-01052-8","article-title":"EGFR is a stable marker of prostate cancer dissemination to bones","volume":"123","author":"Nasta\u0142y","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109486_bb0030","volume":"38","author":"Fadaly","year":"2023","journal-title":"J. Enz. Inhib. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109486_bb0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5306\/wjco.v6.i5.133","article-title":"Colon cancer and the epidermal growth factor receptor: current treatment paradigms, the importance of diet, and the role of chemoprevention","volume":"6","author":"Pabla","year":"2015","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in Cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0045","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1021\/jm0608762","article-title":"Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert pro-apoptotic effects","volume":"49","author":"Antonello","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-025-02652-1","article-title":"Targeting EGFR and PI3K\/mTOR pathways in glioblastoma: innovative therapeutic approaches","volume":"42","author":"Singh","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109486_bb0060","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109486_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109486_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110001","article-title":"EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"119","author":"Liu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0075","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.109486_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104806","article-title":"Comparison of third-generation tyrosine kinase inhibitor (TKI) ponatinib with first- and second-generation TKIs for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and bias-corrected meta-analysis","volume":"213","author":"Raza","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0085","article-title":"Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors","volume":"97","author":"Abdo","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106273","article-title":"Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR\/Topo-1 inhibition","volume":"131","author":"Halim","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ddr.22088","article-title":"Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3-d]pyrimidine derivatives as EGFR inhibitors","volume":"84","author":"Sayed","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2026.109486_bb0100","article-title":"New Pyrazolyl-Thiazolidinone\/Thiazole derivatives as celecoxib\/Dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis, molecular modeling and ADME studies","volume":"38","author":"Fadaly","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117847","article-title":"Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: an updated review","volume":"111","author":"Liu","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0110","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jhet.4589","article-title":"Pyridazinones: a versatile scaffold in the development of potential target-based novel anticancer agents","volume":"60","author":"Singh","year":"2023","journal-title":"J. Heterocyclic Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0115","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1039\/D4MD00481G","article-title":"Pyridazinone-based derivatives as anticancer agents endowed with anti-microbial activity: molecular design, synthesis, and biological investigation","volume":"15","author":"El-Nagar","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107623","article-title":"Synthesis, COX-2 inhibition, anti-inflammatory activity, molecular docking, and histopathological studies of new pyridazine derivatives","volume":"150","author":"Ewieda","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0125","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/ddr.22118","article-title":"Pyridazine derivatives as selective COX-2 inhibitors: a review on recent updates","volume":"84","author":"Ewieda","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2026.109486_bb0130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/molecules28020678","article-title":"Synthesis, spectroscopic characterization, antibacterial activity, and computational studies of novel pyridazinone derivatives","volume":"28","author":"Daoui","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109486_bb0135","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.3390\/molecules28217252","article-title":"Nanoparticles of a pyrazolo-pyridazine derivative as potential EGFR and CDK-2 inhibitors: design, structure determination, anticancer evaluation and in silico studies","volume":"28","author":"Hashem","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109486_bb0140","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1080\/17568919.2024.2379234","article-title":"An overview of pyridazin-3 (2H)-one: a core for developing bioactive agents targeting cardiovascular diseases and cancer","volume":"16","author":"Abd-Rabo","year":"2024","journal-title":"Future Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109486_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10406638.2025.2457951","article-title":"Design and synthesis of new Quinazolinone derivatives conjugated with Chalcone or Pyridazine moieties: anticancer activities and apoptotic induction","volume":"45","author":"Elazab","year":"2025","journal-title":"Polycycl. Aromat. Compd."},{"key":"10.1016\/j.bioorg.2026.109486_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112946","article-title":"Pyridazine as a privileged structure: an updated review on anticancer activity of pyridazine containing bioactive molecules","volume":"209","author":"He","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109486_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"issue":"25","key":"10.1016\/j.bioorg.2026.109486_bb0160","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1200\/JCO.2008.18.8193","article-title":"Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-kit, in patients with advanced or metastatic solid tumors","volume":"27","author":"Eskens","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0165","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12032-023-02174-8","article-title":"Single-cell transcriptomic analysis reveals crucial oncogenic signatures and their associated cell types involved in gastric cancer","volume":"40","author":"Sekaran","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0170","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr-Abl tyrosine kinase inhibitors for overcoming T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"issue":"22","key":"10.1016\/j.bioorg.2026.109486_bb0175","doi-asserted-by":"crossref","first-page":"23713","DOI":"10.1021\/acsomega.4c00794","article-title":"Evaluation of novel Spiro-pyrrolopyridazine derivatives as anticancer compounds: in vitro selective cytotoxicity, induction of apoptosis, EGFR inhibitory activity, and molecular docking analysis","volume":"9","author":"Atmaca","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.109486_bb0180","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109486_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117005","article-title":"Design, synthesis, and cytotoxicity screening of novel pyrazolopyrimidines over renal cell carcinoma (UO-31 cells) as p38\u03b1 inhibitors, and apoptotic cells inducing activities","volume":"281","author":"Ewieda","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109157","article-title":"Design, synthesis, and antitumor evaluation of new pyridazinone scaffolds as dual EGFR\/VEGFR-2 kinase inhibitors and apoptotic cells inducers","volume":"166","author":"Ewieda","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108728","article-title":"Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity","volume":"163","author":"Aboelez","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134216","article-title":"Design, synthesis and chemoinformatic studies of new thiazolopyrimidine derivatives as potent anticancer agents via phosphodiesterase-5 inhibition and apoptotic inducing activity","volume":"1272","author":"Nemr","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109486_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108694","article-title":"Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase-carbonic anhydrase inhibitors with potential anti-tubulin activity","volume":"163","author":"Mohamed","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108672","article-title":"Discovery of novel thiazolopyrimidine derivatives targeting topoisomerase II: design, synthesis, antiproliferative evaluation, molecular docking and apoptosis inducing activity","volume":"163","author":"Ewieda","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0215","article-title":"Design, synthesis and cytotoxic evaluation of new thieno [2, 3-d] pyrimidine analogues as VEGFR-2\/AKT dual inhibitors, apoptosis and autophagy inducers","volume":"150","author":"El-Mawgoud","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107410","article-title":"Novel guanidine derivatives targeting leukemia as selective Src\/Abl dual inhibitors: design, synthesis and anti-proliferative activity","volume":"147","author":"Moustafa","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107881","article-title":"Novel benzenesulfonamide derivatives as potential selective carbonic anhydrase IX, XII inhibitors with anti-proliferative activity: design, synthesis and in silico studies","volume":"153","author":"Fadaly","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107566","article-title":"Design, synthesis, antineoplastic activity of new pyrazolo [3, 4-d] pyrimidine derivatives as dual CDK2\/GSK3\u03b2 kinase inhibitors; molecular docking study, and ADME prediction","volume":"150","author":"Nemr","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109486_bb0235","first-page":"200","article-title":"Synthesis, computer-aided screening and pharmacological evaluation of 2\/3-substituted-6(4-methyl phenyl)-4,5-dihydropyridazin-3(2H)-ones and pyridazine-substituted triazine","volume":"26","author":"Khokra","year":"2015","journal-title":"Indones. J. Pharm."},{"key":"10.1016\/j.bioorg.2026.109486_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105325","article-title":"Design, synthesis, biological evaluation, and molecular docking studies of novel pyrazolo[3,4-d]pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers","volume":"116","author":"Sherbiny","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118348","article-title":"Design and synthesis of new pyridazinone derivatives as selective COX-2 inhibitors: in-vitro and in-vivo evaluation of the anti-inflammatory activity, histopathological studies and molecular modelling","volume":"130","author":"Hassan","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0250","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bioorg.2018.10.067","article-title":"Synthesis, anti-proliferative, Pim-1 kinase inhibitors and molecular docking of thiophenes derived from estrone","volume":"83","author":"Mohareb","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Use of MTT colorimetric assay to measure cell activation","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.109486_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106428","article-title":"Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities","volume":"134","author":"Fadaly","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0265","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1007\/s11030-024-11016-2","article-title":"An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors","volume":"29","author":"Nemr","year":"2025","journal-title":"Mol. Dives."},{"issue":"15","key":"10.1016\/j.bioorg.2026.109486_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202500175","article-title":"Insight study for repurposing of certain anti-inflammatory drugs based on aspirin and salicylic acid scaffolds for the treatment of cancer as CDKs inhibitors: cheminformatics and anticancer studies","volume":"10","author":"Abdalla","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.109486_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108962","article-title":"Indole-imidazolone derivatives as dual Mcl-1\/COX-2 inhibitors: design-oriented synthesis, molecular docking, and dynamics studies with potential anticancer and anti-inflammatory activities","volume":"165","author":"Lamie","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109075","article-title":"Design, synthesis and biological evaluation of novel pyrazoline derivatives as dual EGFR\/VEGFR-2 inhibitors for targeted cancer therapy","volume":"165","author":"Sawiris","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0285","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/j.1349-7006.2007.00580.x","article-title":"ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms","volume":"98","author":"Kong","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.109486_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116979","article-title":"PI3K inhibitor \u201calpelisib\u201d alleviates methotrexate induced liver injury in mice and potentiates its cytotoxic effect against MDA-MB-231 triple negative breast cancer cell line","volume":"488","author":"Gamal","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109486_bb0295","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e12088","article-title":"Effect of PI3K inhibitor LY294002 combined with RAD001, a mTOR specificity inhibitor, on proliferation and apoptosis of triple-negative breast cancer cell lines MDA-MB-231 through PI3K\/AKT\/mTOR pathway in vitro","volume":"33","author":"Gang","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109486_bb0300","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/prot.24339","article-title":"Ligand binding and dynamics of the monomeric epidermal growth factor receptor ectodomain","volume":"81","author":"Loeffler","year":"2013","journal-title":"Proteins"},{"key":"10.1016\/j.bioorg.2026.109486_bb0305","doi-asserted-by":"crossref","first-page":"13403","DOI":"10.1039\/D5NJ01567G","article-title":"Molecular dynamics simulation and free energy analysis of EGFR resistance mutations: implications for the design of novel inhibitors","volume":"49","author":"Wu","year":"2025","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0310","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109486_bb0315","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.109486_bb0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.109486_bb0325","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of drug absorption using multivariate statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109486_bb0330","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:16:45Z","timestamp":1770067005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826000222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":66,"alternative-id":["S0045206826000222"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109486","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel pyridazinone derivatives as EGFRWT\/ EGFRT790M kinase inhibitors; design, synthesis, antitumor evaluation, and molecular dynamic simulations","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109486"}}